Business
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
THOUSAND OAKS, Calif., January 12, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pedia
About this update from Atara Biotherapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3000,"height":912,"url":"https://media.zenfs.com/en/business-wire.com/2ca75027646c7479c943153481e9fc31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Du7QcREL3UtirerH4hUYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2ca75027646c7479c943153481e9fc31","width":960,"height":292},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fnKGgy3HIzD4wq5zkEV4Rw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2ca75027646c7479c943153481e9fc31","width":1200,"height":365}},"lazy":false},{"type":"text","content":"U.S. Food and Drug Administration has issued a Complete Response Letter (CRL)","length":77,"tagName":"p","attribs":{}},{"type":"text","content":"THOUSAND OAKS, Calif., January 12, 2026--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen.","length":735,"tagName":"p"},{"type":"text","content":"The CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form. The BLA was resubmitted in 2025 after reaching alignment with the FDA on the acceptability of the resubmission criteria and fulfilment of the conditions as identified in the first Complete Response Letter dated 15 January 2025 (First CRL). As we previously disclosed, in the First CRL, the FDA identified a single deficiency regarding Good Manufacturing Practice (GMP) compliance and did not raise any concerns with respect to the safety, efficacy or trial design.","length":554,"tagName":"p"},{"type":"text","content":"In the current CRL, received after market close on 9 January 2026, the FDA confi...